Pharmabiz4h
Acurx Pharma receives positive regulatory guidance from EMA for ibezapolstat phase 3 programme for C. difficile infection
Acurx Pharma receives positive regulatory guidance from EMA for ibezapolstat phase 3 programme for C. difficile infection: Staten Island, New York Tuesday, January 7, 2025, 18:00 ...
Pharmabiz5h
Zydus enters agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary
Zydus enters agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary: Our Bureau, Mumbai Tuesday, January 7, 2025, 17:15 Hrs [IST] Zydus L ...
Pharmabiz6h
SunAct Cancer Institute ties up with Singapore’s CytoMed for phase 2 clinical trials on innovative Gamma Delta T-cell cancer therapy in India
Our Bureau, Mumbai Tuesday, January 7, 2025, 16:45 Hrs [IST] ...
Pharmabiz5h
JCR Pharma & Modalis validate initial proof of concept in a joint research programme for development of a novel gene therapy for a CNS disease
JCR Pharma & Modalis validate initial proof of concept in a joint research programme for development of a novel gene therapy for a CNS disease: Hyogo, Japan Tuesday, January 7, 20 ...
Pharmabiz6h
US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with Charcot-Marie-tooth disease
US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with Charcot-Marie-tooth disease: Aarhus, Denmark Tuesday, January 7, 2025, 16:00 Hrs [IST] NMD Ph ...
Pharmabiz7h
eMBR Genomics partners with Axio BioPharma to make MKLP1 Pro antibodies commercially available
MBR Genomics partners with Axio BioPharma to make MKLP1 Pro antibodies commercially available: Madison, Wisconsin Tuesday, January 7, 2025, 15:00 Hrs [IST] In a milestone for cel ...
Pharmabiz7h
RNT Health Insights receives second US FDA breakthrough device designation for esophageal cancer detection tool
RNT Health Insights receives second US FDA breakthrough device designation for esophageal cancer detection tool: Our Bureau, Mumbai Tuesday, January 7, 2025, 15:40 Hrs [IST] RNT H ...
Pharmabiz8h
Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints
Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints: Zug, Switzerland Tuesday, January 7, 202 ...
Pharmabiz11h
Santhera enters supply and distribution agreement with Clinigen Group for Agamree to treat patients with Duchenne muscular dystrophy
Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...
Pharmabiz10h
Biotech Showcase 2025 is set to convene in San Francisco for Biotech Investor Conference
Biotech Showcase 2025 is set to convene in San Francisco for Biotech Investor Conference: Our Bureau, Mumbai Tuesday, January 7, 2025, 12:00 Hrs [IST] Biotech Showcase 2025, an ex ...
Pharmabiz13h
Astellas Pharma’s Vyloy receives China NMPA approval for first-line treatment of advanced gastric or GEJ adenocarcinoma
Astellas Pharma’s Vyloy receives China NMPA approval for first-line treatment of advanced gastric or GEJ adenocarcinoma: Tokyo Tuesday, January 7, 2025, 09:00 Hrs [IST] Astellas ...
Pharmabiz14h
CDSCO establishes Sub-Zonal Office in Bhubaneswar, boosting Odisha’s pharmaceutical sector
CDSCO establishes Sub-Zonal Office in Bhubaneswar, boosting Odisha’s pharmaceutical sector: Shardul Nautiyal, Mumbai Tuesday, January 7, 2025, 08:00 Hrs [IST] In a significant m ...